Dr. Raúl Insa, SOM Biotech CEO, gave an interview to Labiotech.eu, leading digital media covering the European Biotech industry, read by 100000+ monthly visitors.
In this interview, Dr. Insa explained the mission of SOM Biotech, advantages of drug repurposing and aspects of drug development for Orphan diseases. SOM Biotech’s CEO also talked about the current clinical trial run by the company for the treatment of Huntington’s disease, as well as the Company’s future plans. During the interview, the latest licensing deals of SOM Biotech were also stated as well as the recent success of the company in raising a financing round of €7M.
Have a look at the whole interview at https://labiotech.eu/biotech-of-the-week/som-biotech-huntingtons-disease/